Lipocine Inc. Announces Virtual R&D Event to Discuss LPCN 1154 as a Treatment for Postpartum Depression, Highlighting New Phase 3 Study Launch

Reuters

2025/06/23

Lipocine Inc. Announces Virtual R&D Event to Discuss LPCN 1154 as a Treatment for Postpartum Depression, Highlighting New Phase 3 Study Launch

Lipocine Inc. $(LPCN)$, a biopharmaceutical company, has announced an upcoming virtual research and development investor event scheduled for July 9, 2025. The event will discuss LPCN 1154 (BRLIZIO™), a treatment for postpartum depression $(PPD)$. The presentation will feature Dr. Kristina M. Deligiannidis from Zucker Hillside Hospital, Northwell Health, New York, along with company management, who will discuss the current treatment landscape and unmet needs in PPD. Lipocine's LPCN 1154 is noted for its potential as the first line option for rapid symptom relief in women with PPD, with a 48-hour treatment duration in an outpatient setting through an oral form. The event will include updates on clinical, regulatory, and development aspects, particularly focusing on the recently initiated Phase 3 registrational study, which is expected to yield results in Q2-2026. A live Q&A session will follow the presentations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipocine Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA14654) on June 23, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2545419040"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545419040\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545419040?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-23 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545419040","market":"nz","top_or_hot":-1,"title":"Lipocine Inc. Announces Virtual R&D Event to Discuss LPCN 1154 as a Treatment for Postpartum Depression, Highlighting New Phase 3 Study Launch","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lipocine Inc. Announces Virtual R&amp;D Event to Discuss LPCN 1154 as a Treatment for Postpartum Depression, Highlighting New Phase 3 Study Launch\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lipocine Inc. <a href=\"https://laohu8.com/S/LPCN\">$(LPCN)$</a>, a biopharmaceutical company, has announced an upcoming virtual research and development investor event scheduled for July 9, 2025. The event will discuss LPCN 1154 (BRLIZIO™), a treatment for postpartum depression <a href=\"https://laohu8.com/S/PPD\">$(PPD)$</a>. The presentation will feature Dr. Kristina M. Deligiannidis from Zucker Hillside Hospital, Northwell Health, New York, along with company management, who will discuss the current treatment landscape and unmet needs in PPD. Lipocine's LPCN 1154 is noted for its potential as the first line option for rapid symptom relief in women with PPD, with a 48-hour treatment duration in an outpatient setting through an oral form. The event will include updates on clinical, regulatory, and development aspects, particularly focusing on the recently initiated Phase 3 registrational study, which is expected to yield results in Q2-2026. A live Q&amp;A session will follow the presentations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipocine Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA14654) on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lipocine Inc. Announces Virtual R&D Event to Discuss LPCN 1154 as a Treatment for Postpartum Depression, Highlighting New Phase 3 Study Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLipocine Inc. Announces Virtual R&D Event to Discuss LPCN 1154 as a Treatment for Postpartum Depression, Highlighting New Phase 3 Study Launch\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-23 20:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lipocine Inc. Announces Virtual R&amp;D Event to Discuss LPCN 1154 as a Treatment for Postpartum Depression, Highlighting New Phase 3 Study Launch\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lipocine Inc. <a href=\"https://laohu8.com/S/LPCN\">$(LPCN)$</a>, a biopharmaceutical company, has announced an upcoming virtual research and development investor event scheduled for July 9, 2025. The event will discuss LPCN 1154 (BRLIZIO™), a treatment for postpartum depression <a href=\"https://laohu8.com/S/PPD\">$(PPD)$</a>. The presentation will feature Dr. Kristina M. Deligiannidis from Zucker Hillside Hospital, Northwell Health, New York, along with company management, who will discuss the current treatment landscape and unmet needs in PPD. Lipocine's LPCN 1154 is noted for its potential as the first line option for rapid symptom relief in women with PPD, with a 48-hour treatment duration in an outpatient setting through an oral form. The event will include updates on clinical, regulatory, and development aspects, particularly focusing on the recently initiated Phase 3 registrational study, which is expected to yield results in Q2-2026. A live Q&amp;A session will follow the presentations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipocine Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA14654) on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LPCN","symbol_name":"Lipocine Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL3bcPYP:1","article_id":"2545419040","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545419040","pubTimestamp":1750680084,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lipocine Inc. Announces Virtual R&D Event to Discuss LPCN 1154 as a Treatment for Postpartum Depression, Highlighting New Phase 3 Study Launch. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipocine Inc. published the original content used to generate this news brief via PR Newswire  on June 23, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LPCN":"Lipocine Inc","BK4007":"制药"},"translate_title":"Lipocine Inc.宣布举办虚拟研发活动，讨论LPCN 1154作为产后抑郁症的治疗方法，重点介绍新的3期研究启动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LPCN":0.9},"content_text":"Lipocine Inc. Announces Virtual R&D Event to Discuss LPCN 1154 as a Treatment for Postpartum Depression, Highlighting New Phase 3 Study Launch\n    \n\n        Lipocine Inc. $(LPCN)$, a biopharmaceutical company, has announced an upcoming virtual research and development investor event scheduled for July 9, 2025. The event will discuss LPCN 1154 (BRLIZIO™), a treatment for postpartum depression $(PPD)$. The presentation will feature Dr. Kristina M. Deligiannidis from Zucker Hillside Hospital, Northwell Health, New York, along with company management, who will discuss the current treatment landscape and unmet needs in PPD. Lipocine's LPCN 1154 is noted for its potential as the first line option for rapid symptom relief in women with PPD, with a 48-hour treatment duration in an outpatient setting through an oral form. The event will include updates on clinical, regulatory, and development aspects, particularly focusing on the recently initiated Phase 3 registrational study, which is expected to yield results in Q2-2026. A live Q&A session will follow the presentations.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipocine Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA14654) on June 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}